Authors
Loading...
May guide bosentan phase I dosing amid interspecies clearance gaps; leaves open clinical kinetic validation.
Key points are not available for this paper at this time.
Ubeaud et al. (1995) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: